

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM: IDX 1017	11874-016-999 417451-999016)

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that

one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: November 20, 2008 By: [Signature]

Name: MARIA D. STAM

Position: VICE PRESIDENT, PRODUCT DEVELOPMENT

Universita Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

CNRS No.: 85256-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Università Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Università Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that

one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:


Position:

Università Degli Studi di Cagliari

Certifico io Ufficiale Rogante Sostituto dell'Università degli Studi di Cagliari che la firma, apposta in mia presenza dal Prof. Adolfo Lai nato a Ottana, 28.07.1943, Pro Rettore dell'Università di Cagliari e della cui identità personale sono certo, è autentica.

19 DIC. 2008

L'Ufficiale Rogante Sostituto
Dr. Achille Filiberto Putzu



Name: **ADOLFO LAI**

Position: **PRO RETTORE UNIVERSITÀ DI CAGLIARI**

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that

one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____
Name:
Position:

Universita Degli Studi di Cagliari

Date: _____ By: _____
Name:
Position:

Centre National de la Recherche Scientifique

Date: 04 DEC. 2008 By: Directeur de la Politique Industrielle
Name: Marc J. LEDOUX
Position: _____

